Chemomab Therapeutics (CMMB) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 49.5% versus a loss of 60.3%. Over five years, CMMB leads with a -96.2% price change compared with -99.8% for TOVX. Theriva Biologics is the larger company by market cap ($10.4 million vs $10.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | TOVX |
|---|---|---|
| Share price | $1.39 | $0.2271 |
| Market cap | $10.19M | $10.42M |
| 1-day change | +2.21% | -2.95% |
| YTD return | -15.76% | +8.14% |
| 1-year return | -60.29% | -49.53% |
| 5-year return | -96.18% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-1.04 | $0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $0.86 |
| 52-week low | $1.05 | $0.16 |
| Distance from 52-week high | -60.85% | -73.59% |
| Analyst consensus | none | none |
| Avg. price target upside | +259.71% | +1000.84% |
| Average volume | 118.53K | 530.02K |
| Shares outstanding | 7.33M | 45.89M |
| Employees | — | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed CMMB by 10.8 percentage points over the past year.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Healthcare · Biotechnology
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Healthcare · Biotechnology · 15 employees
CMMB vs TOVX FAQ
Which is bigger, Chemomab Therapeutics or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $10.42M compared with $10.19M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, CMMB or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -60.29% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.